Search hospitals > Illinois > Chicago
University of Chicago Comprehensive Cancer Center
Claim this profileChicago, Illinois 60637
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Ovarian Cancer
Conducts research for Lung Cancer
Conducts research for Pancreatic Cancer
594 reported clinical trials
51 medical researchers
Summary
University of Chicago Comprehensive Cancer Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreatic Cancer and other specialties. University of Chicago Comprehensive Cancer Center is involved with conducting 594 clinical trials across 749 conditions. There are 51 research doctors associated with this hospital, such as Rita Nanda, MD, Ardaman Shergill, MD, Ami V Desai, and Christine M. Bestvina.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage I
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Rita Nanda, MDUniversity of Chicago Comprehensive Cancer Center8 years of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
24 reported clinical trials
47 drugs studied
Ardaman Shergill, MDUniversity of Chicago Comprehensive Cancer Center2 years of reported clinical research
Studies Colorectal Cancer
Studies Pancreatic Cancer
25 reported clinical trials
63 drugs studied
Ami V DesaiUniversity of Chicago Comprehensive Cancer Center4 years of reported clinical research
Expert in Neuroblastoma
Studies Cancer
22 reported clinical trials
45 drugs studied
Christine M. BestvinaUniversity of Chicago Comprehensive Cancer Center6 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
21 reported clinical trials
38 drugs studied
Clinical Trials running at University of Chicago Comprehensive Cancer Center
Lung Cancer
Cancer
Breast Cancer
Esophageal cancer
Pancreatic Cancer
Breast cancer
Ovarian Cancer
Prostate Cancer
Stomach Cancer
Kidney Cancer
Radiation Therapy
for Brain Metastasis
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. FSRS delivers a high dose of radiation to the tumor over 3 treatments. SRS is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. FSRS may be more effective compared to SRS in treating patients with cancer that has spread to the brain.
Recruiting2 awards Phase 312 criteria
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Chicago Comprehensive Cancer Center?
University of Chicago Comprehensive Cancer Center is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Pancreatic Cancer and other specialties. University of Chicago Comprehensive Cancer Center is involved with conducting 594 clinical trials across 749 conditions. There are 51 research doctors associated with this hospital, such as Rita Nanda, MD, Ardaman Shergill, MD, Ami V Desai, and Christine M. Bestvina.
Where is University of Chicago Comprehensive Cancer Center located?
**Directions to the Center for Care and Discovery:**
- From the north, take the Kennedy Expressway (I-90) east or Edens Expressway (I-94) south.
- Merge onto the Dan Ryan Expressway (I-90/94) east.
- Exit at 55th Street (Garfield Boulevard) and follow signs to 5700 S. Maryland Ave.
Who should I call to ask about financial aid or insurance network?
For insurance inquiries at the University of Chicago Comprehensive Cancer Center, email Benefits@uchicago.edu or call 773-702-9634. For financial assistance, download the application in English or Spanish, attach supporting documents, and mail to The University of Chicago Medicine, 150 Harvester Dr., Ste 300, Burr Ridge, IL 60527-5965. For billing questions, contact (773) 702-6664 or send mail to the same address.
What insurance does University of Chicago Comprehensive Cancer Center accept?
The University of Chicago Comprehensive Cancer Center accepts a broad spectrum of insurance plans, such as Aetna, AIG Medical, American Health Holding, Blue Cross Blue Shield PPO, Cigna, Coventry Health Care of Illinois (PersonalCare) HMO, Health Alliance PPO, Humana, Medicaid (Illinois), Medicare, MultiPlan PPO, and United Healthcare Choice Plus (POS/PPO). This includes commercial insurance plans, exchange or health insurance marketplace plans, and Medicare and Medicare Advantage insurance plans. Please contact your insurance company to confirm coverage before receiving services.
What awards or recognition has University of Chicago Comprehensive Cancer Center received?
The University of Chicago Comprehensive Cancer Center (UCCCC) has been an NCI-Designated Cancer Center since 1973 and achieved comprehensive status in 2008. It is renowned for its contributions to basic and clinical research, especially in drug development and early-phase clinical trials, enrolling about 1,000 patients annually. The center excels in genetic classification of hematological malignancies, cancer immunology, pharmacogenomics, and cancer genetics, among other areas, and has earned significant accolades including the Leapfrog Group's Top Teaching Hospital and the Magnet Recognition Program designation.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.